About Kelsey Cramer
Kelsey Cramer, MSN, AGACNP-BC, DNP, is a board-certified adult-gerontology acute care nurse practitioner specializing in pulmonary medicine at Froedtert & the Medical College of Wisconsin. She focuses on interstitial lung disease (ILD), pulmonary hypertension (PH), and sarcoidosis. Kelsey earned her MSN from Depaul University in Chicago, and her DNP from Rush University. She is dedicated to delivering patient-centered care, education, and support for those managing complex lung conditions.
ILD Digital Learning Center by Kelsey Cramer
Podcasts
Podcasts
Advances in IPF Clinical Trials
August 2026
29:40 m
In this ILD Community Network Podcast episode, host Kelsey Cramer is joined by Kristy Delaney for a timely discussion on advances in idiopathic pulmonary fibrosis clinical trials and the evolving treatment landscape for IPF and progressive pulmonary fibrosis. Together, they review the TETON clinical development program, including TETON 1, TETON 2, and TETON PPF, and explore the scientific rationale for studying inhaled treprostinil in pulmonary fibrosis following findings from the INCREASE trial. This episode highlights key clinical trial insights related to forced vital capacity, disease progression, time to clinical worsening, background anti-fibrotic therapy, safety, tolerability, cough management, and the potential role of inhaled therapy as an add-on or alternative option for patients with IPF or PPF. Clinicians will gain practical perspective on emerging IPF research, patient selection for new therapies, treatment layering strategies, clinical trial considerations, and how advanced practice providers can stay informed as therapeutic options for interstitial lung disease continue to expand.
The Role of APPs in Advanced ILD/PH ILD
August 2026
18:12 m
In this ILD Community Network podcast episode, host Kelsey Cramer is joined by Jenny Williams, for a practical discussion on the role of advanced practice providers in advanced interstitial lung disease and pulmonary hypertension associated with interstitial lung disease, also known as PH-ILD. Together, they explore how APPs can recognize high-risk signs of disease progression, including worsening shortness of breath, declining exercise tolerance, increasing oxygen needs, changes in pulmonary function tests, reduced six-minute walk distance, and signs of right heart strain or pulmonary hypertension. This episode also highlights when clinicians should consider referral to ILD specialty centers, pulmonary hypertension clinics, lung transplant evaluation, pulmonary rehab, anti-fibrotic therapy, inhaled therapy for PH-ILD, and palliative care support. Listeners will gain practical insights into identifying advanced ILD, understanding PH-ILD risk factors, recognizing transplant referral triggers, coordinating multidisciplinary care, and ensuring patients receive timely access to specialized treatment and advanced therapies.
FAQ
FAQ
FAQ: How Can Pulmonology and Rheumatology Providers Coordinate Earlier PH-ILD Diagnosis?
August 2026
01:33 m
In this ILD Community Network video, Kelsey Cramer, NP, an interstitial lung disease and pulmonary hypertension specialist from the Medical College of Wisconsin and Froedtert Hospital, discusses how pulmonology and rheumatology providers can better coordinate earlier diagnosis of pulmonary hypertension in patients with interstitial lung disease. She highlights the importance of building multidisciplinary connections, creating trusted referral pathways, and reaching out to colleagues across specialties to improve patient care. This episode also reviews key diagnostic tools that can support earlier PH recognition, including echocardiograms, high-resolution CT scans, pulmonary function tests, diffusion capacity, forced vital capacity, and right heart catheterization. Clinicians will gain practical insight into identifying red flags, such as a DLCO that is out of proportion to FVC, and learn how earlier testing and collaboration can help guide therapy, speed diagnosis, and improve outcomes for patients living with ILD and pulmonary hypertension.
Webcast
Webcast
Recognizing and Managing RA-Associated ILD
August 2026
39:02 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Amanda Sell, PA-C and Kelsey Cramer, MSN, AGACNP-BC, DNP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
33:58 m
This webcast presents a case-based discussion on identifying and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Amanda Sell, PA-C and Kelsey Cramer, AGACNP-BC, DNP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The discussion also underscores the importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care, including transplant evaluation, to improve patient outcomes.
Industry Resources
WANT EXPERT PERSPECTIVES ON INTERSTITIAL LUNG DISEASE?